Cargando…
Efficacy of dipeptidyl peptidase-4 inhibitor linagliptin in patients with type 2 diabetes undergoing hemodialysis
BACKGROUND: Incretin therapy is feasible in patients with type 2 diabetes mellitus undergoing hemodialysis (HD). However, few studies have examined the safety and efficacy of this therapeutic approach in patients with diabetes and renal impairment. Here, we examined glycemic control and the anti-oxi...
Autores principales: | Terawaki, Yuichi, Nomiyama, Takashi, Takahashi, Hiroyuki, Tsutsumi, Yoko, Murase, Kunitaka, Nagaishi, Ryoko, Tanabe, Makito, Kudo, Tadachika, Kobayashi, Kunihisa, Yasuno, Tetsuhiko, Nakashima, Hitoshi, Yanase, Toshihiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4438630/ https://www.ncbi.nlm.nih.gov/pubmed/25995772 http://dx.doi.org/10.1186/s13098-015-0043-2 |
Ejemplares similares
-
Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury
por: Terawaki, Yuichi, et al.
Publicado: (2014) -
Combined Treatment with Exendin-4 and Metformin Attenuates Prostate Cancer Growth
por: Tsutsumi, Yoko, et al.
Publicado: (2015) -
Reduced vascular events in type 2 diabetes by biguanide relative to sulfonylurea: study in a Japanese Hospital Database
por: Tanabe, Makito, et al.
Publicado: (2015) -
Prescription of oral hypoglycemic agents for patients with type 2 diabetes mellitus: A retrospective cohort study using a Japanese hospital database
por: Tanabe, Makito, et al.
Publicado: (2016) -
Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice
por: Takahashi, Hiroyuki, et al.
Publicado: (2019)